{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:43:41Z","timestamp":1789681421522,"version":"4.0.1"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.blre.2024.101171","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T05:46:02Z","timestamp":1705815962000},"page":"101171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["When anticoagulation management in atrial fibrillation becomes difficult: Focus on chronic kidney disease, coagulation disorders, and cancer"],"prefix":"10.1016","volume":"65","author":[{"given":"Panteleimon E.","family":"Papakonstantinou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Kalogera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Charitos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Benia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Batsouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Lampropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Xydonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiraj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2024.101171_bb0005","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke."},{"key":"10.1016\/j.blre.2024.101171_bb0010","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","article-title":"Stroke severity in atrial fibrillation","volume":"27","author":"Lin","year":"1996","journal-title":"Framingham Study Stroke"},{"key":"10.1016\/j.blre.2024.101171_bb0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2024.101171_bb0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-0041-1739411","article-title":"2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary","volume":"122","author":"Chao","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101171_bb0025","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s40266-018-0587-6","article-title":"Frailty status affects the decision for long-term anticoagulation therapy in elderly patients with atrial fibrillation","volume":"35","author":"Papakonstantinou","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.blre.2024.101171_bb0030","first-page":"11","article-title":"Direct Oral anticoagulants for stroke prevention in special populations: beyond the clinical trials","author":"Carbone","year":"2023","journal-title":"Biomedicines."},{"key":"10.1016\/j.blre.2024.101171_bb0035","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/eurjpc\/zwab021","article-title":"Anticoagulation therapy in non-valvular atrial fibrillation in the COVID-19 era: is it time to reconsider our therapeutic strategy?","volume":"29","author":"Papakonstantinou","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0040","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/jcm13010216","article-title":"Direct Oral anticoagulants in special patient populations","volume":"13","author":"Kessler","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2024.101171_bb0045","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.2174\/1381612826666200420150517","article-title":"Anticoagulation in deep venous thrombosis: current trends in the era of non- vitamin K antagonists Oral anticoagulants","volume":"26","author":"Papakonstantinou","year":"2020","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.blre.2024.101171_bb0050","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.jacc.2019.08.1031","article-title":"Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week","volume":"74","author":"Kumar","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0055","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ahj.2009.06.031","article-title":"Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study","volume":"158","author":"Watanabe","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.blre.2024.101171_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19031436","article-title":"Safety and efficacy of DOACs in patients with advanced and end-stage renal disease","volume":"19","author":"Rogula","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.blre.2024.101171_bb0065","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jacc.2016.06.057","article-title":"Atrial fibrillation and thromboembolism in patients with chronic kidney disease","volume":"68","author":"Lau","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0070","article-title":"Atrial fibrillation in chronic kidney disease: An overview","volume":"14","author":"Gadde","year":"2022","journal-title":"Cureus."},{"key":"10.1016\/j.blre.2024.101171_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12959-019-0211-y","article-title":"Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study","volume":"17","author":"Laugesen","year":"2019","journal-title":"Thromb J"},{"key":"10.1016\/j.blre.2024.101171_bb0080","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1161\/CIRCULATIONAHA.122.061647","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and end-stage renal disease: lessons learned","volume":"146","author":"Benz","year":"2022","journal-title":"Circulation."},{"key":"10.1016\/j.blre.2024.101171_bb0085","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1055\/s-0042-1750385","article-title":"Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific expert consensus paper","volume":"122","author":"Gorog","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101171_bb0090","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101171_bb0095","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101171_bb0100","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101171_bb0105","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101171_bb0110","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/ckj\/sfy133","article-title":"Anticoagulant-related nephropathy: systematic review and meta-analysis","volume":"12","author":"de Aquino Moura","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.blre.2024.101171_bb0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.17219\/acem\/142657","article-title":"Anticoagulant-related nephropathy: focus on novel agents. A review","volume":"31","author":"Zakrocka","year":"2022","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.blre.2024.101171_bb0120","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1111\/bcp.14688","article-title":"Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: analysis of the Japanese adverse drug event report database","volume":"87","author":"Mitsuboshi","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.blre.2024.101171_bb0125","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/j.jacc.2016.08.063","article-title":"Acute kidney injury in Asians with atrial fibrillation treated with dabigatran or warfarin","volume":"68","author":"Chan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2018.02.075","article-title":"The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: a nationwide cohort study in Taiwan","volume":"265","author":"Chan","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0135","doi-asserted-by":"crossref","first-page":"306","DOI":"10.5853\/jos.2020.01886","article-title":"Anticoagulation in patients with end-stage renal disease and atrial fibrillation: confusion, concerns and consequences","volume":"22","author":"Goel","year":"2020","journal-title":"J Stroke"},{"key":"10.1016\/j.blre.2024.101171_bb0140","first-page":"9","article-title":"Oral anticoagulants, time in therapeutic range and renal function over time in real-life patients with atrial fibrillation and chronic kidney disease","author":"Batra","year":"2022","journal-title":"Open Heart"},{"key":"10.1016\/j.blre.2024.101171_bb0145","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist Oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace."},{"key":"10.1016\/j.blre.2024.101171_bb0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijcard.2022.01.063","article-title":"Renal decline in patients with non-valvular atrial fibrillation treated with rivaroxaban or warfarin: a population-based study from the United Kingdom","volume":"352","author":"Gonz\u00e1lez P\u00e9rez","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0155","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619868535","article-title":"Rivaroxaban\u2019s impact on renal decline in patients with Nonvalvular atrial fibrillation: a US MarketScan claims database analysis","volume":"25","author":"Coleman","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.blre.2024.101171_bb0160","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/03007995.2022.2061705","article-title":"Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study","volume":"38","author":"Vaitsiakhovich","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.blre.2024.101171_bb0165","first-page":"57","article-title":"Oral anticoagulant treatment in patients with atrial fibrillation and chronic kidney disease","author":"Stoica","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.blre.2024.101171_bb0170","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"83","author":"Joglar","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12882-022-03041-w","article-title":"UK prescribing practice of anticoagulants in patients with chronic kidney disease: a nephrology and haematology-based survey","volume":"24","author":"Parker","year":"2023","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.blre.2024.101171_bb0180","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/europace\/euz358","volume":"22","author":"Potpara","year":"2020","journal-title":"Europace."},{"key":"10.1016\/j.blre.2024.101171_bb0185","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijcard.2016.11.303","article-title":"Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: a systematic review and network meta-analysis","volume":"231","author":"And\u00f2","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0190","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease","volume":"141","author":"Stanifer","year":"2020","journal-title":"Circulation."},{"key":"10.1016\/j.blre.2024.101171_bb0195","first-page":"100813","article-title":"Rivaroxaban vs vitamin K antagonist in patients with atrial fibrillation and advanced chronic kidney disease","volume":"vol. 3","author":"Kreutz","year":"2024","journal-title":"JACC"},{"key":"10.1016\/j.blre.2024.101171_bb0200","doi-asserted-by":"crossref","first-page":"105","DOI":"10.31083\/j.rcm2303105","article-title":"Insights into concomitant atrial fibrillation and chronic kidney disease","volume":"23","author":"Wang","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.blre.2024.101171_bb0205","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrneph.2018.19","article-title":"Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction","volume":"14","author":"Potpara","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.blre.2024.101171_bb0210","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with Apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.blre.2024.101171_bb0215","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban pharmacokinetics at steady state in hemodialysis patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.blre.2024.101171_bb0220","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/eurheartj\/ehy060","article-title":"Chronic kidney disease and arrhythmias: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"39","author":"Turakhia","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2024.101171_bb0225","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/CIRCULATIONAHA.123.065614","article-title":"Associations of Apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease","volume":"148","author":"Xu","year":"2023","journal-title":"Circulation."},{"key":"10.1016\/j.blre.2024.101171_bb0230","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","article-title":"Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study","volume":"64","author":"Bonde","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0235","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2016-000441","article-title":"Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis","volume":"3","author":"Nochaiwong","year":"2016","journal-title":"Open Heart"},{"key":"10.1016\/j.blre.2024.101171_bb0240","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacc.2019.10.059","article-title":"Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis","volume":"75","author":"Kuno","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0245","doi-asserted-by":"crossref","DOI":"10.1177\/20543581211046079","article-title":"Time in therapeutic range using a nomogram for dose adjustment of warfarin in patients on hemodialysis with atrial fibrillation","volume":"8","author":"Defoe","year":"2021","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.blre.2024.101171_bb0250","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation."},{"key":"10.1016\/j.blre.2024.101171_bb0255","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing Apixaban with the vitamin K antagonist Phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation."},{"key":"10.1016\/j.blre.2024.101171_bb0260","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/ndt\/gfx265","article-title":"Atrial fibrillation in kidney transplant recipients: is there a place for the novel drugs?","volume":"33","author":"Malyszko","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.blre.2024.101171_bb0265","first-page":"7","article-title":"Epidemiology and prognostic importance of atrial fibrillation in kidney transplant recipients: a meta-analysis","author":"Thongprayoon","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2024.101171_bb0270","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/17512433.2019.1637733","article-title":"Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy","volume":"12","author":"Lam","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.blre.2024.101171_bb0275","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14474","article-title":"Can direct oral anticoagulants be used in kidney transplant recipients?","volume":"35","author":"Parker","year":"2021","journal-title":"Clin Transplant"},{"key":"10.1016\/j.blre.2024.101171_bb0280","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/pace.13331","article-title":"Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis","volume":"41","author":"Chokesuwattanaskul","year":"2018","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.blre.2024.101171_bb0285","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood-2016-01-692814","article-title":"Age-sex-specific ranges of platelet count and all-cause mortality: prospective findings from the MOLI-SANI study","volume":"127","author":"Bonaccio","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2024.101171_bb0290","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012596","article-title":"Thrombocytopenia and mortality risk in patients with atrial fibrillation: An analysis from the START registry","volume":"8","author":"Pastori","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.blre.2024.101171_bb0295","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.hrthm.2018.08.023","article-title":"Prognostic efficacy of platelet count in patients with nonvalvular atrial fibrillation","volume":"16","author":"Park","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.blre.2024.101171_bb0300","doi-asserted-by":"crossref","first-page":"e0224709","DOI":"10.1371\/journal.pone.0224709","article-title":"Thrombocytopenia and thrombocytosis are associated with different outcome in atrial fibrillation patients on anticoagulant therapy","volume":"14","author":"Michowitz","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2024.101171_bb0305","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.critrevonc.2018.09.014","article-title":"Antithrombotic medication in cancer-associated thrombocytopenia: current evidence and knowledge gaps","volume":"132","author":"Leader","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2024.101171_bb0310","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-014-2198-6","article-title":"Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study","volume":"94","author":"Kopolovic","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2024.101171_bb0315","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.thromres.2017.05.007","article-title":"Safety and efficacy of warfarin in patients with moderate thrombocytopenia","volume":"155","author":"Lai","year":"2017","journal-title":"Thromb Res"},{"issue":"24","key":"10.1016\/j.blre.2024.101171_bb0320","first-page":"7516","article-title":"Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation. Blood Adv","volume":"7","author":"Iyengar","year":"2023"},{"key":"10.1016\/j.blre.2024.101171_bb0325","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s11239-018-1792-1","article-title":"Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia","volume":"47","author":"Wang","year":"2019","journal-title":"J Thromb Thrombolysis."},{"key":"10.1016\/j.blre.2024.101171_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2022.03.011","article-title":"Oral anticoagulant use for patients with atrial fibrillation with concomitant Anemia and\/or thrombocytopenia","volume":"135","author":"Yeh","year":"2022","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2024.101171_bb0335","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral factor Xa inhibitor with low molecular weight heparin in patients with Cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2024.101171_bb0340","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of Cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101171_bb0345","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1055\/s-0038-1668523","article-title":"Apixaban versus Dalteparin for the treatment of acute venous thromboembolism in patients with Cancer: the Caravaggio study","volume":"118","author":"Agnelli","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101171_bb0350","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/FJC.0000000000000607","article-title":"Non-vitamin K antagonist Oral anticoagulants in patients with atrial fibrillation and thrombocytopenia","volume":"72","author":"Janion-Sadowska","year":"2018","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.blre.2024.101171_bb0355","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjh.14714","article-title":"Current challenges and future prospects in oral anticoagulant therapy","volume":"178","author":"Czuprynska","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101171_bb0360","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1111\/hae.12525","article-title":"Management of atrial fibrillation in people with haemophilia--a consensus view by the ADVANCE Working Group","volume":"20","author":"Schutgens","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2024.101171_bb0365","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/bloodadvances.2021005260","article-title":"Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study","volume":"6","author":"Van Der Valk","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.blre.2024.101171_bb0370","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1160\/TH12-05-0332","article-title":"Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients","volume":"109","author":"Fransen van de Putte","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101171_bb0375","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood-2015-12-635094","article-title":"How I treat patients with inherited bleeding disorders who need anticoagulant therapy","volume":"128","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101171_bb0380","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1517\/14656566.2012.656591","article-title":"Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia","volume":"13","author":"Mannucci","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.blre.2024.101171_bb0385","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/CRD.0000000000000045","article-title":"Consensus review of the treatment of cardiovascular disease in people with hemophilia a and B","volume":"23","author":"Ferraris","year":"2015","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.blre.2024.101171_bb0390","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5482\/HAMO-16-09-0037","article-title":"Management of cardiovascular disease in aging persons with haemophilia","volume":"37","author":"Schutgens","year":"2017","journal-title":"Hamostaseologie."},{"key":"10.1016\/j.blre.2024.101171_bb0395","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest."},{"key":"10.1016\/j.blre.2024.101171_bb0400","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-0040-1718410","article-title":"Long-Term Antithrombotic Treatments Prescribed for Cardiovascular Diseases in Patients with Hemophilia: Results from the French Registry","volume":"121","author":"Guillet","year":"2021","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.blre.2024.101171_bb0405","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-07-727032","article-title":"New concepts for anticoagulant therapy in persons with hemophilia","volume":"128","author":"Schutgens","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2024.101171_bb0410","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/jth.13674","article-title":"Comparing thrombin generation in patients with hemophilia a and patients on vitamin K antagonists","volume":"15","author":"de Koning","year":"2017","journal-title":"J Thromb Haemostas"},{"key":"10.1016\/j.blre.2024.101171_bb0415","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.jacc.2016.09.944","article-title":"Causes of death in anticoagulated patients with atrial fibrillation","volume":"68","author":"G\u00f3mez-Outes","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0420","doi-asserted-by":"crossref","first-page":"9169","DOI":"10.4081\/hr.2021.9169","article-title":"Apixaban and eftrenonacog alfa treatment in a patient with moderate hemophilia B and cardiovascular disease","volume":"13","author":"Santoro","year":"2021","journal-title":"Hematol Rep"},{"key":"10.1016\/j.blre.2024.101171_bb0425","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10840-021-01090-z","article-title":"Left atrial appendage occlusion in haemophilia patients with atrial fibrillation","volume":"64","author":"Kramer","year":"2022","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.blre.2024.101171_bb0430","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2019.044","article-title":"Direct Oral anticoagulants in patients affected by major congenital thrombophilia","volume":"11","author":"Serrao","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.blre.2024.101171_bb0435","first-page":"486","article-title":"Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study","volume":"18","author":"Margaglione","year":"2020","journal-title":"Blood Transf"},{"key":"10.1016\/j.blre.2024.101171_bb0440","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018917","article-title":"Direct Oral anticoagulants in patients with inherited thrombophilia and venous thromboembolism: a prospective cohort study","volume":"9","author":"Campello","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.blre.2024.101171_bb0445","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2024.101171_bb0450","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2024.101171_bb0455","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101171_bb0460","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2024.101171_bb0465","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101171_bb0470","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/jth.14935","article-title":"Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Zuily","year":"2020","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.blre.2024.101171_bb0475","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/MBC.0000000000001021","article-title":"Direct oral anticoagulants in patients with antiphospholipid syndrome: a retrospective study in a real-life patient cohort","volume":"33","author":"Franke","year":"2022","journal-title":"Blood Coagul Fibrinol"},{"key":"10.1016\/j.blre.2024.101171_bb0480","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11739-008-0124-4","article-title":"First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation","volume":"3","author":"Guzzetti","year":"2008","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.blre.2024.101171_bb0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102861","article-title":"Atrial fibrillation as a marker of occult cancer","volume":"9","author":"Ostenfeld","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.blre.2024.101171_bb0490","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/eurjpc\/zwaa087","article-title":"Anticoagulation for atrial fibrillation in active cancer: what the cardiologists think","volume":"28","author":"Farmakis","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0495","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0500","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-oncology drug interactions: a scientific statement from the American Heart Association","volume":"145","author":"Beavers","year":"2022","journal-title":"Circulation."},{"key":"10.1016\/j.blre.2024.101171_bb0505","series-title":"Ibrutinib-Associated Atrial Fibrillation JACC Clinical Electrophysiology","first-page":"1491","volume":"4","author":"Ganatra","year":"2018"},{"key":"10.1016\/j.blre.2024.101171_bb0510","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jacc.2019.01.017","article-title":"Anticoagulation strategies in patients with Cancer: JACC review topic of the week","volume":"73","author":"Mosarla","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0515","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009543","article-title":"Atrial fibrillation and risk of Cancer: a Danish population-based cohort study","volume":"7","author":"Vinter","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.blre.2024.101171_bb0520","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11739-022-03156-w","article-title":"Bleeding and thrombotic events in atrial fibrillation patients with cancer: a systematic review and meta-analysis","volume":"18","author":"Pastori","year":"2023","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.blre.2024.101171_bb0525","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.026388","article-title":"Performance of the HAS-BLED, ORBIT, and ATRIA bleeding risk scores on a cohort of 399344 hospitalized patients with atrial fibrillation and Cancer: data from the French National Hospital Discharge Database","volume":"11","author":"Pastori","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.blre.2024.101171_bb0530","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/2047487318759858","article-title":"CHA(2)DS(2)-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer","volume":"25","author":"D\u2019Souza","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0535","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2024.101171_bb0540","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/cncr.33470","article-title":"Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study","volume":"127","author":"Pastori","year":"2021","journal-title":"Cancer."},{"key":"10.1016\/j.blre.2024.101171_bb0545","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejim.2022.08.004","article-title":"Adherence to the \u201catrial fibrillation better care\u201d (ABC) pathway in patients with atrial fibrillation and cancer: a report from the ESC-EHRA EURObservational research Programme in atrial fibrillation (EORP-AF) general long-term registry","volume":"105","author":"Vitolo","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.blre.2024.101171_bb0550","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3892\/ol.2022.13244","article-title":"Anticoagulation for atrial fibrillation in active cancer","volume":"23","author":"Farmakis","year":"2022","journal-title":"Oncol Lett"},{"key":"10.1016\/j.blre.2024.101171_bb0555","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40959-017-0021-y","article-title":"Management of atrial fibrillation in patients taking targeted cancer therapies","volume":"3","author":"Asnani","year":"2017","journal-title":"Cardio Oncol (Lond Engl)"},{"key":"10.1016\/j.blre.2024.101171_bb0560","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.18060","article-title":"Oral anti-coagulant treatment patterns in atrial fibrillation patients diagnosed with cancer: a Danish nationwide cohort study","volume":"197","author":"Ording","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101171_bb0565","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/eurjpc\/zwaa054","article-title":"Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management","volume":"28","author":"Boriani","year":"2021","journal-title":"Eur J Prev Cardiol."},{"key":"10.1016\/j.blre.2024.101171_bb0570","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11239-022-02717-2","article-title":"Net clinical benefit of DOACs vs. usual anticoagulation treatment in venous thromboembolism and active cancer: systematic review and meta-analysis","volume":"55","author":"Michalopoulou","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.blre.2024.101171_bb0575","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ehjqcco\/qcy040","article-title":"Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF","volume":"5","author":"Chen","year":"2019","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.blre.2024.101171_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and safety of Apixaban versus warfarin in patients with atrial fibrillation and a history of Cancer: insights from the ARISTOTLE trial","volume":"130","author":"Melloni","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2024.101171_bb0585","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008987","article-title":"Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 trial","volume":"7","author":"Fanola","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.blre.2024.101171_bb0590","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11239-020-02304-3","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis","volume":"51","author":"Mariani","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.blre.2024.101171_bb0595","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012540","article-title":"Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: a systematic review and meta-analysis","volume":"8","author":"Deng","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.blre.2024.101171_bb0600","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2459\/JCM.0000000000001041","article-title":"Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis","volume":"21","author":"Casula","year":"2020","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.blre.2024.101171_bb0605","doi-asserted-by":"crossref","first-page":"7079","DOI":"10.1002\/cam4.4241","article-title":"Mortality associated with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: dabigatran versus rivaroxaban","volume":"10","author":"Lin","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2024.101171_bb0610","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/tri.13599","article-title":"Safety and efficacy of direct-acting oral anticoagulants versus warfarin in kidney transplant recipients: a retrospective single-center cohort study","volume":"33","author":"Bixby","year":"2020","journal-title":"Transpl Int"},{"key":"10.1016\/j.blre.2024.101171_bb0615","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.blre.2024.101171_bb0620","doi-asserted-by":"crossref","first-page":"E112","DOI":"10.1002\/ajh.25045","article-title":"Safety of anticoagulation in patients with atrial fibrillation and MDS\/AML complicated by thrombocytopenia: An unresolved challenge: can they be managed? A report of three cases and literature review","volume":"93","author":"Caro","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101171_bb0625","first-page":"18","article-title":"Haemophilia and atrial fibrillation- Acase report","volume":"27","author":"Serrano","year":"2021","journal-title":"Haemophilia."},{"key":"10.1016\/j.blre.2024.101171_bb0630","article-title":"Catheter ablation for atrial fibrillation in patients with hemophilia or von Willebrand disease","volume":"3","author":"van der Valk","year":"2019","journal-title":"TH Open"},{"key":"10.1016\/j.blre.2024.101171_bb0635","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.autrev.2018.04.009","article-title":"Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis","volume":"17","author":"Dufrost","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2024.101171_bb0640","series-title":"Direct Oral Anticoagulants in Patients with Antiphospholipid Syndrome: a Cohort Study","first-page":"37","volume":"29","author":"Malec","year":"2020"},{"key":"10.1016\/j.blre.2024.101171_bb0645","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jth.15158","article-title":"Trial of rivaroxaban in AntiPhospholipid syndrome (TRAPS): two-year outcomes after the study closure","volume":"19","author":"Pengo","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101171_bb0650","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cam4.1054","article-title":"Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study","volume":"6","author":"Ording","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2024.101171_bb0655","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4070\/kcj.2017.0328","article-title":"Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer","volume":"48","author":"Kim","year":"2018","journal-title":"Korean Circ J."},{"key":"10.1016\/j.blre.2024.101171_bb0660","first-page":"706","article-title":"Superior safety of direct oral anticoagulants compared to warfarin in patients with atrial fibrillation and underlying cancer: a national veterans affairs database study","volume":"16","author":"Sawant","year":"2019","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.blre.2024.101171_bb0665","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101171_bb0670","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2169\/internalmedicine.2415-18","article-title":"Oral anticoagulants in Japanese patients with atrial fibrillation and active Cancer","volume":"58","author":"Yasui","year":"2019","journal-title":"Internal Med (Tokyo, Japan)"},{"key":"10.1016\/j.blre.2024.101171_bb0675","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7150\/jca.36468","article-title":"Novel Oral anticoagulant versus warfarin in Cancer patients with atrial fibrillation: An 8-year population-based cohort study","volume":"11","author":"Wu","year":"2020","journal-title":"J Cancer"},{"key":"10.1016\/j.blre.2024.101171_bb0680","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1161\/STROKEAHA.120.033470","article-title":"Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study","volume":"52","author":"Chan","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.blre.2024.101171_bb0685","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaccao.2021.06.004","article-title":"Effectiveness and safety of Oral anticoagulants among Nonvalvular atrial fibrillation patients with active Cancer","volume":"3","author":"Deitelzweig","year":"2021","journal-title":"JACC Cardio Oncol"},{"key":"10.1016\/j.blre.2024.101171_bb0690","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1002\/cam4.4012","article-title":"Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants","volume":"10","author":"Ording","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2024.101171_bb0695","doi-asserted-by":"crossref","first-page":"e008951","DOI":"10.1161\/CIRCOUTCOMES.122.008951","article-title":"Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults With Cancer and Atrial Fibrillation","volume":"15","author":"Mehta","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"10.1016\/j.blre.2024.101171_bb0700","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jaccao.2022.07.004","article-title":"Outcomes by class of anticoagulant use for Nonvalvular atrial fibrillation in patients with active Cancer","volume":"4","author":"Potter","year":"2022","journal-title":"JACC Cardio Oncol"},{"key":"10.1016\/j.blre.2024.101171_bib701","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12959-023-00563-7","article-title":"Safety and efficacy of direct oral anticoagulants in stroke prevention in patients with atrial fibrillation complicated with anemia and\/or thrombocytopenia: a retrospective cohort study","volume":"21","author":"Xu","year":"2023","journal-title":"Thrombosis Journal"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T15:26:55Z","timestamp":1713367615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X24000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":141,"alternative-id":["S0268960X24000043"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2024.101171","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When anticoagulation management in atrial fibrillation becomes difficult: Focus on chronic kidney disease, coagulation disorders, and cancer","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2024.101171","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101171"}}